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Inter-individual variation in response to drugs conveys considerable risk of either 
therapy failure or drug toxicity. Caffeine, as one of the most frequently used 
psychoactive substances in the world, is not an exception, and both lack of effects and 
adverse reactions have been observed after usual doses. In addition to inter-individual 
differences at the drug-receptor level and drug-drug interactions, variability in caffeine 
metabolism has been proposed as a possible explanation. The objective of this study 
was to investigate the influence of pharmacogenetic and environmental factors, which 
are known to be of importance for inter-individual variation in drug disposition, on the 
activity of enzymes involved in caffeine metabolism, namely cytochrome P450 1A2 
(CYP1A2) and 2A6 (CYP2A6), N-acetyltransferase-2 (NAT2) and xanthine oxidase 
(XO).  
 
The study involved unrelated healthy volunteers from three ethnically distinct 
populations: Serbian (n=140), Swedish (n=190) and Korean (n=150). Phenotyping of 
CYP1A2, CYP2A6, NAT2 and XO was performed using caffeine as a probe drug and 
measuring concentration of parent compound and its metabolites in plasma or urine 
samples. CYP1A2 activity was estimated by 17X/137X plasma ratio, and CYP2A6, 
NAT2 and XO activities were determined by 17U/17X, AFMU/(AFMU+1X+1U) and 
1U/(1U+1X) urinary ratios, respectively. In addition, subjects were genotyped for the 
most important CYP1A2, CYP2A6 and NAT2 polymorphisms.  
 
Daily consumption of at least three cups of coffee in non-OC (oral contraceptive) users 
significantly increased CYP1A2 enzyme activity in both Swedes (P<0.0001) and Serbs 
(P=0.0002). When additionally controlling for smoking, the observed difference 
remained significant in both populations (P≤0.02). Significant association of heavy 
coffee consumption with high CYP1A2 enzyme activity was observed only in carriers 
of −163 A/A, and increasing effect of −163C>A on CYP1A2 inducibility was found in 
both Serbian (P=0.022) and Swedish (P=0.016) nonsmoking heavy coffee consumers. 
There was no significant difference in CYP1A2 enzyme activity among genotypes in 
non–heavy coffee consumers. Controlling for the effect of smoking, heavy coffee 
consumption habit and OC use, significantly lower 17X/137X ratio was observed in 
Serbs than in Swedes (P=0.0003). Comparison between Swedes and Koreans revealed 
that functional CYP2A6 alleles were more frequent in former, whereas the defective 
were more frequent in latter (P≤0.002). CYP2A6 genotype significantly affected 
enzyme activity in both populations (P=0.004), while no effect of sex, age, cigarette 
smoking or OC use was observed. CYP2A6 activity was higher in Swedes compared to 
Koreans, with 3.16% of Swedes and 18.75% of Koreans being slow metabolizers 
(P=0.0001). The observed differences between the two populations remained 
significant when controlling for the genotype effect, i.e. within rapid (P=0.0007) and 
intermediate (P=0.04) genotype groups. Rapid acetylator was the predominant NAT2 
phenotype in Serbs, present in 55% of the population. Significant NAT2 genotype-
phenotype association was detected in Serbs (P<0.0001), Swedes (P=0.03) and Koreans 
(P=0.008). Partial NAT2 genotype-phenotype discordance in Serbian rapid acetylators 
could not be explained by NAT1 gene polymorphism. Koreans displayed significantly 
  
higher NAT2 activity compared to Swedes, and the difference remained significant 
when controlling for the influence of cigarette smoking, sex, or OC use (P <0.0001), as 
well as NAT2 genotype (P=0.016). Swedes and Koreans significantly differed in terms 
of NAT2 genotype groups distribution (P<0.0001). Stratified by genotype, among 
carriers of at least one wild type NAT2*4 allele Koreans displayed higher enzyme 
activity compared to Swedes (P=0.004). No significant influence of smoking or sex on 
NAT2 activity was observed in Serbs, Swedes or Koreans. OC use significantly 
increased NAT2 activity in Swedish women (P=0.007). In terms of XO activity, no 
significant difference between Swedes and Koreans was detected. In Swedes, higher 
XO activity was observed in women compared to men (P=0.003), and the effect 
remained significant after controlling for OC use (P=0.01). OC use and cigarette 
smoking did not affect XO activity in either Swedes or Koreans. 
 
In conclusion, habitual heavy coffee consumption induces CYP1A2 enzyme activity in 
carriers of CYP1A2 −163 A/A genotype. CYP2A6 genotype, but not sex, age, cigarette 
smoking and OC use, significantly affect CYP2A6 enzyme activity. NAT2 genotype, 
but not sex and cigarette smoking, significantly affect NAT2 enzyme activity. Cigarette 
smoking and OC use do not affect XO enzyme activity. In Swedes, female sex and oral 
contraceptive use are associated with higher XO and NAT2 enzyme activities, 
respectively. Swedes display significantly higher CYP1A2 and CYP2A6 activities 
compared to Serbs and Koreans, respectively. Koreans display significantly higher 
NAT2 enzyme activity compared to Swedes. Serbs differ from other Caucasians in 
terms of N-acetylation capacity, due to unprecedented high prevalence of rapid 
acetylator phenotype. There is no inter-ethnic difference between Swedes and Koreans 
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1 INTRODUCTION  
1.1  VARIATION IN DRUG DISPOSITION 
Inter-individual variability in response to drugs represents an important problem in 
clinical practice, as it conveys considerable risk of either lack of efficacy or 
development of adverse effects and toxicity in patients on generally accepted and 
recommended therapy regimen (1-3). This could be due to the differences in drug 
disposition, i.e. pharmacokinetics (absorption, distribution, metabolism and 
elimination), in drug pharmacodynamics, which is related to drug target, or both (4, 5). 
Although all drugs exhibit certain variability, the highest potential for clinically 
significant event is observed in those with narrow therapeutic range and extensive 
metabolism (4-6).  
 
To ensure maximal efficacy and safety of drug therapy, physicians need to choose 
and prescribe an appropriate medication at the right dose for each patient (5, 7). Due 
to inter-individual variability in drug disposition and response, numerous factors, 
classified as either intrinsic or extrinsic, have to be taken into account. Typical 
intrinsic factors are related to the individual, and include body weight, age, gender, 
concomitant diseases, and genetics. On the other hand, typical extrinsic factors are 
related to the environment that the individual is exposed to, including concomitant drug 
use, dietary intake, as well as exposure to certain substances such as tobacco and 
alcohol (3, 4, 8-10).  
 
Although recognized as building bricks of inter-individual differences, certain intrinsic 
and extrinsic factors could be shared among individuals, assembling them into 
populations that differ among each other in terms of drug disposition and response (11, 
12). Populations that share “common traits and customs”, such as genetic heritage, 
social background and environment, are regarded as ethnic populations (13, 14). 
Therefore, ethnicity has been accepted as a multidimensional determinant of described 
inter-individual variability (3, 9, 14-16). 
 
Swedes belong to Scandinavian i.e. northern European population and live on the 
eastern side of the Scandinavian Peninsula, located at the far north of the Europe (17, 
18). Serbs belong to the South Slavic Europeans that primarily inhabit central and 
western part of the Balkan Peninsula, known as the gate between the Europe and the 
Near East (19-21). Both Swedish and Serbian populations belong to Caucasians (20, 
22). On the other hand, Korean population belongs to Asians and populates Korean 
Peninsula, which extends toward the south from the east part of the Asian continent 
(22, 23). 
 
1.1.1  Pharmacogenetics 
Genetic polymorphisms are naturally existing variants of the gene that are present in at 
least 1% of the population (24). Three major types of genetic polymorphisms are single 
nucleotide polymorphisms (SNPs), insertions/deletions (indels), and copy number 
variations (CNVs). Their functional effects depend on their localization within the gene 
or its flanking regions, and range from complete lack of protein production to induction 
of gene expression (5, 25). It has been estimated that up to 95% of inter-individual 
variability in drug disposition and response could be explained by genetic 
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polymorphisms alone, or by its interaction with other intrinsic and extrinsic factors 
(24).  
 
Genetics can affect efficacy and safety of any drug whose pharmacokinetics or 
pharmacodynamics are regulated by proteins encoded by polymorphically expressed 
genes (6, 8, 24). Nevertheless, probably the most important source of phenotypically 
evident genetic variability lies within drug metabolizing enzymes that control phase I or 
phase II reactions (5-8, 25). Depending on the existing variants of the metabolizing 
enzyme coding gene, resulting phenotype can range from poor metabolizer, which can 
cause drug accumulation and toxicity, to ultrarapid metabolizer, leading to fast drug 
elimination and likely failure of the therapy (6, 10). The science that deals with the role 
of genetics in drug response is called pharmacogenetics (6). 
 
1.1.2  Environmental factors 
To date, numerous environmental factors influencing drug disposition and response 
have been identified, including nutrition components, cigarette smoking, alcohol, 
drugs and herbal products, as well as different xenobiotics present in food, water, soil 
or air, such as polycyclic aromatic hydrocarbons, dioxins, organic solvents, and 
organophosphate insecticides (26). Environmental factors may interact with drugs at 
different levels, increasing or decreasing their activity or toxicity. Yet, the most 
common interactions involve drug metabolizing enzymes and result in metabolism 
induction or inhibition (5).  
 
The mechanism behind enzyme induction involves enhanced synthesis by activation 
of ligand-regulated transcription factors (e.g. induction of CYP1A2 by cigarette 
smoking) (27), or enzyme stabilization following transcription (e.g. induction of 
CYP2E1 by alcohol intake) (28). On the other hand, enzyme inhibition refers to 
competition for the enzyme’s active site (e.g. inhibition of CYP3A4 by indinavir) 
(29), or binding to a separate site on the enzyme or to enzyme-substrate complex, 
making the enzyme nonfunctional (e.g. inhibition of CYP3A4 by erythromycin) (26). 
The clinical consequences of metabolism induction or inhibition by environmental 
factors range from therapeutic failure to adverse drug effects and drug toxicity (30). 
 
1.2  CAFFEINE  
Caffeine (1,3,7-trimethylxanthine) is an alkaloid naturally present in seeds, leaves or 
fruit of plants such as coffee (Coffea sp.), tea (Camellia sinensis), cocoa (Theobroma 
cacao), kola (Cola acuminate), yerba mate (Ilex paraguariensis), and guarana 
(Paullinia cupana) (31). History of caffeine use dates back thousands of years: first tea 
consumption has been attributed to Chinese emperor Shen Nung and his accidental 
discovery of the drink in 2737 B.C, while indulging in coffee originates from Ethiopia 
and is credited to goat herder Khaldi, who lived around 850 A.D (32-34). Not until 16th 
and 17th century caffeine consumption became widespread, yet today it represents one 
of the most frequently used psychoactive substances in the world (35). Variety of 
common beverages, products containing cocoa or chocolate, as well as certain 
medications, contains caffeine (31, 35, 36). Nevertheless, its primary source is coffee, 
delivering approximately 70% of all consumed caffeine to about one-third of the world 
population on a daily basis (34, 37). 
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Caffeine acts through multiple mechanisms, including inhibition of phosphodiesterase 
and blockade of γ-aminobutyric acid (GABA) receptors, but its competitive antagonism 
of adenosine effects is the most important at typical plasma concentrations (32, 36, 38, 
39). Adenosine is an endogenous purine nucleoside that at physiological levels 
preferentially activates its A1 and A2A receptors, primarily localized in the brain (32, 
40-42). Blockade of both A1 and A2A receptors prevents adenosine-induced GABA 
inhibition of dopaminergic system and increases the release of various 
neurotransmitters, and it is responsible for stimulating effects of caffeine (35, 40, 42).  
 
In moderate doses, caffeine increases vigilance, endurance and neuromuscular 
coordination, improves mood and cognitive performance and decreases anxiety and 
fatigue (32, 35, 38, 39, 41, 43). In addition, it elevates circulating catecholamine levels 
and basal metabolism, promote lipolysis and help in weight loss, while in sensitive 
individuals may even raise systolic blood pressure (32, 35, 42). In clinical practice, 
caffeine is used as an analgesic in combination with aspirin, acetaminophen, codeine or 
ergotamine, but also as a short-term treatment of neonatal apnea of prematurity (44). 
With chronic caffeine use, the tolerance to its effects can develop within hours or days, 
and the reason is considered to be upregulation of A1 receptors (32, 39). When the 
regular consumption of coffee is discontinued, the same mechanism causes the caffeine 
withdrawal syndrome, characterized by headache and fatigue as the most prominent 
symptoms, followed by irritability, nausea and vomiting. Withdrawal symptoms 
typically begin at 12-24 hours and peak at 20-48 hours after cessation of caffeine 
consumption, disappear within the three days after the last caffeine dose, but may 
persist for a week (32, 35, 40, 41, 43).  
 
Very high doses of caffeine could lead to tachycardia, nausea, anxiety, restlessness and 
tremors (42), while the acute toxic dose of caffeine in adults has been estimated to 
approximately 10 grams per day (32, 42). On the other hand, moderate daily 
consumption of up to 400 mg of caffeine, except in childhood and pregnancy, should 
pose no risks to human health. Furthermore, beneficial effects of regular caffeine 
intake, including prevention of Parkinson’s disease, diabetes mellitus or skin cancer, 
have been discovered (39, 42). However, not everyone respond to caffeine as described, 
so both lack of effects and adverse reactions have been observed after usual doses. In 
addition to inter-individual differences at the drug-receptor level and drug-drug 
interactions, variability in caffeine pharmacokinetics has been proposed as a possible 
explanation (1, 35).  
 
Pharmacokinetics of caffeine has been widely investigated, and its basic principles are 
already well known. After ingestion, caffeine undergoes rapid and complete absorption 
from the gastrointestinal tract, reaching 100% bioavailability and the peak plasma level 
between 30 and 75min (31, 36). Due to its lipophilic properties and low plasma protein 
binding, caffeine easily penetrates all biologic membranes, including placental and 
blood-brain barrier (32, 38). It has an average half-life of about 4 to 6 hours and a total 
clearance of approximately 2ml/min/kg (36, 38). Only 2-3% of ingested dose is 
excreted unchanged in urine (36, 45). Metabolism of caffeine exhibits linear 
pharmacokinetics, which becomes saturated at doses higher than 250mg. It is mainly 
restricted to liver, and involves several drug-metabolizing enzymes, including 
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cytochrome P450 1A2 and 2A6, N-acetyltransferase-2 and xanthine oxidase (45-49) 
(Figure 1). Since it is safe and inexpensive, with rapid and complete absorption and 
metabolism short half-life, caffeine is considered an ideal probe drug for estimation of 
in vivo activity of these enzymes (47). 
 
Figure 1. Caffeine metabolism in humans. 
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1.2.1  CYP1A2 
Cytochrome P450 1A2 (CYP1A2) is an important phase I hepatic enzyme that 
metabolizes various endogenous substrates, such as steroid hormones, arachidonic acid 
and melatonin, and activates several procarcinogens, e.g. arylamines and aflatoxin B1. 
Moreover, it is involved in biotransformation of more than 100 clinically used drugs, 
including antipsychotics clozapine, olanzapine and haloperidol, antidepressants 
amitriptyline and imipramine, sedative diazepam, analgesic acetaminophen, 
cardiovascular drugs propranolol, verapamil, anticoagulant warfarin, as well as 
theophylline and caffeine (48, 50-52). 
 
CYP1A2 gene is located on chromosome 15 (15q22 – q24), spans about 7.8 kb and 
comprises 7 exons (50, 53). To date, numerous variations of CYP1A2 gene have been 
reported (http://www.cypalleles.ki.se/cyp1a2.htm). However, only few of them have 
been associated with alteration in enzyme activity: substitution C>A at position −163 
(rs762551), which tags CYP1A2*1F allele, leads to increased enzyme inducibility (54), 
while carriers of CYP1A2*1C (−3860G>A, rs2069514) display decreased CYP1A2 
activity (55). Single nucleotide polymorphism (SNP) -163C>A represents common 
CYP1A2 polymorphism, observed at 60-70% frequency in many Caucasian, Asian and 
African populations (27, 56, 57). On the other hand, −3860G>A was found to be 
mainly present in Asia (the frequency of about 25%), while it is extremely rare in other 
populations (27, 56, 57). 
 
CYP1A2 activity has been reported to vary significantly among individuals, resulting in 
up to 40-fold difference in steady-state plasma concentration of substrate (52, 58). This 
wide variation has been attributed to either genetic or environmental factors (58). It has 
been shown that 42, 38, and 33% of the catalytic activity, protein expression, and 
mRNA levels, respectively, seem to be due to genetic variation of CYP1A2 (52). 
Environmental factors of influence include cigarette smoking (27), charcoal-grilled 
meat (59), omeprazole (56) and carbamazepine (60) as inducers, and oral 
contraceptives (27), fluvoxamine (61) and fluoroquinolone antibiotics (52) as 
inhibitors. Investigations of gender difference in CYP1A2 activity (27, 62, 63) or 
possible influence of caffeine consumption (63, 64) gave inconclusive results. Inter-
ethnic differences in CYP1A2 activity have been reported as lower enzyme activity in 
black compared to white populations (62, 65). 
 
As the metabolism of caffeine is more than 90% dependent on CYP1A2 
(transformation of caffeine into its main metabolite 17X), its clearance is considered the 
standard probe for assessment of CYP1A2 activity (48, 52, 58). Many urine caffeine 
metabolic ratios, such as (17X+17U)/137X (66) and (AFMU+1X+1U)/17U (64), have 
been used, but plasma or saliva 17X/137X ratio has been suggested as the most 
appropriate for estimation of in vivo CYP1A2 activity (46, 67, 68). 
 
1.2.2  CYP2A6 
Cytochrome P450 2A6 (CYP2A6) is another phase I metabolizing enzyme, expressed 
mainly in the liver, which is important for metabolism of steroids and fatty acids and 
activation of procarcinogenes (e.g. nitrosamines and aflatoxin B1). In addition, it plays 
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an essential role in biotransfomation of certain drugs, including antiepileptic valproic 
acid, anestetics halothane and methoxyflurane, aldehyde dehydrogenase inhibitor 
disulfiram, chemotherapeutic drugs cyclophosphamide, iphosphamide and tegafur, well 
as nicotine and caffeine (50, 69-72). 
 
CYP2A6 gene has been mapped to chromosome 19 (19q12 – q13.2), spans a region of 
about 6 kb and comprises 9 exons (69), and it is highly polymorphic 
(http://www.cypalleles.ki.se/cyp2a6.htm). Many of the described variants are 
nonsynonimous, e.g. CYP2A6*4 (gene deletion) and CYP2A6*5 (1436G>T, 
rs5031017) completely lack enzyme activity, CYP2A6*7 (1412T>C, rs5031016), 
CYP2A6*8 (1454G>T, rs28399468) and CYP2A6*9 (-48T>G, rs28399433) decrease 
CYP2A6, while CYP2A6 duplication corresponds to the presence of three copies of the 
gene and thus provides about 1.4-fold higher enzyme activity (73-77). 
 
Wide inter-individual variations in CYP2A6 activity (more than 100-fold) that have 
been observed seem to be affected by a variety of factors (69, 72). It has been shown 
that certain drugs, including rifampicin, dexamethasone, phenobarbital and oral 
contraceptives (50), act as inducers, whereas liver diseases, such as viral hepatitis A or 
alcohol-induced cirrhosis (69), as well as consumption of grapefruit juice and intake of 
ketokonazole (50, 78, 79), decrease CYP2A6 activity. Several previous studies 
described inhibitory effect of cigarette smoking on CYP2A6 enzyme activity (80, 81), 
while some researchers (82, 83), but not all (84, 85), reported sex as a factor of 
influence. Nevertheless, genetic polymorphisms of the CYP2A6 gene are considered the 
major cause for the observed inter-individual variability of CYP2A6 enzyme activity 
(69, 75, 86). Pronounced inter-ethnic variations in CYP2A6 activity and expression 
have been observed as well, usually due to the well-known difference in the frequency 
of CYP2A6 alleles among populations (69). 
 
In the metabolism of caffeine, CYP2A6 participates in the hydroxylation of the caffeine 
metabolite 17X to yield 17U (48). Due to its favorable pharmacokinetics properties and 
proven safety, caffeine test is considered valid and useful method for estimation of in 
vivo CYP2A6 activity (72, 84). To assess enzymatic activity of CYP2A6, urinary 
metabolic ratios 17U/(17U+17X/137X+1U+1X+AFMU) (85) or 17U/17X (87) have 
been used successfully. 
 
1.2.3  NAT2 
Arylamine N-acetyltransferase 2 (NAT2) is a phase II enzyme with predominant 
localization in the liver, where it participates in metabolism of many xenobiotics (88). 
Substrates for NAT2 include commonly used drugs, such as antibacterials isoniazid, 
sulfamethoxazole and dapsone, chemotherapeutic drug aminoglutethimide, 
antiarrhythmic procainamide, anti-inflammatory drug 5-aminosalicylic acid, 
antihypertensives hydralazine and acebutolol, MAO inhibitor phenelzine, as well as 
caffeine (89-93). In addition, it metabolizes several environmental toxicants, including 
potentially carcinogenic heterocyclic amines present in well-cooked red meat and 
cigarette smoke (92). 
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NAT2 gene is located on chromosome 8 (8p21.3-23.1) and consists of one intronless 
open reading frame of 870 bp (92-94). More than 60 variant alleles of NAT2 gene have 
been identified so far (http://louisville.edu/medschool/pharmacology/consensus-human-
arylamine-n-acetyltransferase-genenomenclature/nat_pdf_files/Human_NAT2_alleles. 
pdf/view). The presence of at least one wild-type NAT2*4 or variant *11 (481C>T, 
rs1799929), *12 (803A>G, rs1208), *13 (282C>T, rs1041983) and *18 (845A>C, 
rs56054745) allele provides normal enzyme activity (92, 95). The rest of the NAT2 
allelic variants usually share one or more common missense single nucleotide 
polymorphisms, resulting in decreased expression, low activity, or enzyme instability 
(89, 92, 95). 
 
Wide range of N-acetylation activity has been observed, classifying individuals as slow, 
intermediate, or rapid acetylators (92, 93). NAT2 is not inducible to a significant extent 
in vivo (79, 89). Instead, NAT2 genetic polymorphism is considered the most important 
underlying cause of the described variability (89, 92, 95, 96). It has been shown that 
frequencies of NAT2 SNPs differ among ethnic populations, leading to substantial inter-
ethnic variability in N-acetylation capacity (79, 88, 90, 92, 93, 97). 
 
NAT2 participates in metabolism of caffeine by converting 17X into AFMU (48, 49). 
Since it is much safer than other NAT2 probe drugs, e.g. sulfamethazine or isoniazid, 
caffeine test is considered the most appropriate for the assessment of in vivo N-
acetylation status (92). Both AFMU/1X and AFMU/(AFMU+1X+1U) urinary ratios 
are proved to be reliable indicators of NAT2 enzyme activity (62, 84, 92, 98). 
 
1.2.4  XO 
Xanthine oxidase (XO) is an important phase I enzyme, in humans predominantly 
expressed in the liver and intestine (99-101). It catalyzes essential constitutive reactions 
involving endogenous purines, pyrimidines and aldehydes, with the conversion of 
hypoxanthine to xanthine and further to uric acid as one of its primary roles (100, 102-
107). In addition, XO is responsible for biotransformation of several xenobiotics, 
including clinically important drugs such as allopurinol, acyclovir, mercaptopurine, 
azathioprine, pyrazinamide, methotrexate, fluorouracil, doxorubicin, daunomycin, and 
mitomycin C, as well as caffeine (99-101, 103, 106-108).  
 
The human XO gene is localized on chromosome 2 (2p22), it consists of 36 small 
exons spanning a region of over 60 kbp (100, 104). Variations of the gene have been 
described, but they rarely proved to be functional (91, 101). 
 
There are marked inter-individual and inter-ethnic differences in XO activity, with 
approximately 20% of Caucasians, 11% of Japanese and 4% of Ethiopians displaying 
lower enzyme activity (62, 84, 101, 109, 110). In addition, XO can be up- or down-
regulated under a variety of non-genetic factors (104). It has been observed that its level 
and activity increases during certain diseases, such as arthritis, asthma, viral hepatitis, 
and hypoxia-reperfusion injury (104-108, 111, 112), and the inducing effect has been 
attributed to cytokines, including tumor necrosis factor-α, interleukin-1β, and 
interferon-γ (104, 105). XO activity can be induced by xenobiotics too, both drugs 
(dexamethasone, ethacrynic acid and iron) and hepatotoxic agents, such as halothane 
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alcohol, carbon tetrachloride and 2,3,7,8-tetrachlorodibenzo-p-dioxin (91, 101, 106, 
107, 113). On the other hand, XO can be inhibited by allopurinol and its metabolite 
oxypurinol, and this effect serves as a foundation in the treatment of hyperuricemia and 
its complications (91, 106, 107). It is generally accepted that cigarette smoking does not 
affect XO activity (84, 108, 110), but numerous investigations of possible sex 
differences yielded contradictory results (62, 84, 99, 102, 108, 110). 
 
XO participates in the metabolism of caffeine by converting 1X to 1U (47). Thus, 
caffeine as a probe and urinary (1U)/(1X+1U) ratio has been accepted as appropriate 
for estimation of in vivo XO enzyme activity (47, 91, 99, 101, 103). 
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2 OBJECTIVES 
The general objective of the study was to investigate the influence of pharmacogenetic 
and environmental factors on the activity of drug metabolizing enzymes involved in 
caffeine disposition, namely CYP1A2, CYP2A6, NAT2 and XO, in three ethnically 
distinct populations: Serbs, Swedes and Koreans. 
 
Specific objectives of the study were as follows: 
 
1. To investigate the effect of regular heavy coffee consumption, CYP1A2 
genotype and ethnicity on CYP1A2 enzyme activity (papers I, II). 
2. To investigate the effect of sex, age, cigarette smoking, OC use, CYP2A6 
genotype and ethnicity on CYP2A6 enzyme activity (paper V). 
3. To investigate the effect of sex, cigarette smoking, OC use, NAT2 genotype and 
ethnicity on NAT2 enzyme activity (papers III, IV). 
4. To investigate the effect of sex, cigarette smoking, OC use and ethnicity on XO 
enzyme activity (paper IV). 
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3 MATERIALS AND METHODS 
3.1  SUBJECTS 
The study involved unrelated healthy volunteers of three distinct ethnic origins: 
Serbian, Swedish and Korean. Serbs (n=140) were 18 to 46 years old (median age: 27 
years), and the group included 72 men, 38 smokers (smoking on average two or more 
cigarettes per day), 47 heavy coffee consumers (regularly drinking three or more cups 
of coffee per day), and no oral contraceptive (OC) users. Swedes (n=190) were 18 to 60 
years old (median age: 29 years), and in the group there were 79 men, 39 smokers, 63 
heavy coffee consumers and 44 OC users. Koreans (n=150) were 20 to 46 years old 
(median age: 25 years) and included 74 men, 28 smokers and only one OC user, while 
the data on regular coffee consumption were not available. None of the study subjects 
used any medications, were pregnant or breast-feeding. 
 
As some of the data, including genotyping and phenotyping results, were missing at 
random (could not be obtained for some of the subjects), subjects with missing data 
were excluded from certain analyses, i.e. complete case analysis approach was 
introduced. In addition, some of the analyses required specific exclusion criteria to be 
met, e.g. in paper II the effect of heavy coffee consumption could not be tested in 
smokers. Therefore, the sample size differed: paper I included 100 Serbs and 149 
Swedes, paper II were based on the data obtained from 126 Serbs and 114 Swedes, 
paper III involved 140 Serbs, 113 Swedes and 150 Koreans participated in paper IV, 
while 190 Swedes and 144 Koreans took part in paper V.  
 
3.2  STUDY DESIGN 
All study subjects were advised to abstain from any form of caffeine intake, including 
coffee, tea, chocolate and other caffeine-containing food or beverage consumption, for 
at least (114) 24 h prior to and throughout the study. After completing the wash-out 
period, subjects received single oral dose of 100 mg caffeine (Koffein Recip; Recip 
AB, Årsta, Sweden) and answered a detailed questionnaire about their smoking habit, 
regular coffee consumption and OC use (115).  
 
Four hours after caffeine intake (68), a 20-ml venous blood sample was drawn into 
EDTA-containing vacutainer tubes (Sarstedt, Nümbrecht, Germany): 10ml was kept as 
a whole blood sample, and 10ml was centrifuged and plasma separated. In addition, 8-
hours urine was collected, pH adjusted to 3.5 with 0.1 M HCl to ensure the stability of 
AFMU (85) and 20-ml aliquots were stored.  
 
All samples were frozen at −80°C. Blood and plasma samples collected outside 
Stockholm (in Serbia and Korea) were packed on dry ice and sent to Karolinska 
University Hospital, Huddinge, Sweden, where genotyping and CYP1A2 phenotyping 
analyses were performed. Urine samples were sent to Extremadura University in 
Badajoz, Spain, for CYP2A6, NAT2 and XO phenotype analyses. 
   11 
3.3  LABORATORY ANALYSES 
3.3.1  Genotyping 
Genomic DNA was extracted from the whole blood samples using QIAamp DNA Mini 
Kit (QIAGEN GmbH, Hilden, Germany). DNA concentration and purity were 
measured using DU®530 Life Science UV/Visible Spectrophotometer (Beckman 
Coulter, Fullerton, CA).  
 
Genotyping for CYP1A2 polymorphisms (paper II) -3860G>A (rs2069514), -
739T>G (rs2069526), -729C>T (rs12720461), -163C>A (rs762551), 2159G>A 
(rs2472304), 4795G>A (rs12904742) was carried out using the tag-array 
minisequencing method according to Lindros et al.(116). In brief, DNA fragments 
spanning CYP1A2 polymorphic sites of interest were amplified by multiplex PCR 
reaction, using six PCR primer pairs on GeneAmp® PCR System 2700 (Applied 
Biosystems, Foster City, CA). After removing excess of PCR primers and dNTPs, 
products of multiplex PCR reaction were subjected to minisequencing reaction on PTC-
225 Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA), with the extension mix that 
contained fluorophore-labelled ddNTPs and tagged minisequencing primers. Multiplex 
PCR and minisequencing primers were designed by OligoPerfect Designer 
(www.invitrogen.com) and Auto-Primer software (http://www.autoprimer.com/), 
respectively, and purchased from Integrated DNA Technologies (IDT, Coralville, IA, 
USA). Products of minisequencing reaction were then pipetted onto the microarray, 
spotted with oligonucleotides complementary to the “tag” sequence of the 
minisequencing primers. After completed hybridization, fluorescence signals from 
microarray were measured using ScanArray Express HT® microarray scanner (Perkin 
Elmer Life and Analytical Sciences, Inc., Waltham, MA) and QuantArray® 2001 
software, version 3.0.0.0 (Packard BioScience Company, Meriden, CT). The 
QuantArray file was exported and analysed using the SNPSnapper analysis software, 
version 4.0 beta, (http://www.bioinfo.helsinki.fi/SNPSnapper). SNPs were detected 
based on the type of the fluorescence signal (Texas-Red–ddATP, Tamra–ddCTP, 
R110–ddGTP, Cy5–ddUTP) received from the specific position on the microarray.  
 
In addition, CYP1A2 polymorphism −2467delT (rs35694136) was determined by PCR-
RFLP method described by Chida et al. (117). In short, the fragment of CYP1A2 
spanning the SNP was amplified in the PCR reaction on GeneAmp® PCR System 9700 
(Perkin-Elmer Applied Biosystems, Foster City, CA) and then subjected to the 
restriction enzyme NdeI (New England Biolabs, Ipswich, MA). As enzyme cuts only 
wild type allele to fragments of 149 bp and 18 bp, SNP detection was conducted using 
electrophoresis on 2% agarose gel. 
 
Genotyping for CYP2A6 polymorphisms (paper V) gene deletion, gene conversion in 
the 3′ region, 1436G>T (rs5031017), 1412T>C (rs5031016), 1454G>T (rs28399468) 
and gene duplication was carried out using the AS-PCR methods, as previously 
described in the literature. In brief, gene deletion was detected using nested AS-PCR 
reaction (118), with the first PCR reaction used to amplify the region common for both 
CYP2A6 and CYP2A7 genes, followed by a second amplification with primers specific 
for either wild type or CYP2A6del allele. Gene conversion in the 3′ region and 
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1436G>T were also detected by nested AS-PCR reaction (119), where the first PCR 
reaction was common for both SNPs, and the allelic discrimination was performed 
separately with different primer pairs. Similar nested AS-PCR methods was used for 
separate genotyping of 1412T>C (rs5031016) and 1454G>T (rs28399468) (120). 
Genotyping for gene duplication was performed by one-step AS-PCR method, with 
either CYP2A7-specific or CYP2A6-specific forward primer in addition to CYP2A7 
reverse to distinguish between the wild-type CYP2A7 and the duplicated CYP2A6, 
respectively (76). All PCR reactions were performed on GeneAmp PCR System 2700 
(Applied Biosystems, Foster City, CA), and the products were detected by 
electrophoresis on 1.2% agarose gel. 
 
CYP2A6 polymorphism −48T>G (rs28399433) was determined using newly designed 
nested AS-PCR method. First PCR reaction was performed with 5’-
TGGCTGTGTCCCAAGCTAGGCA-3’ as forward and 5’-CTTCATGAGGGAGTT 
GTACATC-3’ as reversed primer, in the following conditions: initial denaturation at 
95°C for 1 min; 35 cycles of denaturation at 95°C for 15 s, annealing at 56°C for 20 s, 
extension at 72°C for 90 s; final extension at 72°C for 7 min. In AS-PCR reaction, 
allele-specific forward primer 5’-CTTTTTCAGGCAGTAT-3’ or 5’-CTTTTTCAG 
GCAGTAG-3’ was used with the common 5’- CTTCATGAGGGAGTTGTACATC-3’ 
reversed primer, and the reaction conditions were as follows: initial denaturation at 
95°C for 1 min; 15 cycles of denaturation at 95°C for 15 s, annealing at 54°C for 20 s, 
and extension at 72°C for 45 s; and final extension at 72°C for 7 min. PCR reactions 
were performed on GeneAmp PCR System 2700 (Applied Biosystems, Foster City, 
CA). PCR products were detected by electrophoresis on 1.2% agarose gel.  
 
Genotyping for NAT2 polymorphisms (papers III, IV) 190C>T (rs1805158), 
403C>G (rs12720065), 411T>A (rs4986997), 590G>A (rs1799930), 803A>G 
(rs1208), and 857G>A (rs1799931) were carried out using the tag-array 
minisequencing method according to according to Lindros et al.(116), as described 
above. NAT2 polymorphisms 191G>A (rs1801279), 282C>T (rs1041983), 341T>C 
(rs1801280), and 481C>T (rs1799929) were detected using restriction fragment length 
polymorphism (RFLP) or allele-specific (AS) PCR reaction, as reported by Anitha and 
Banerjee (121). Briefly, after amplifying approximately 1.2 kb of NAT2 gene region of 
interest, PCR products were separately digested by the restriction enzymes MspI, FokI 
and KpnI (New England Biolabs, Ipswich, MA) and the pattern of restrictions were 
examined to detect 191G>A, 282C>T and 481C>T, respectively. On the other hand, to 
distinguish between T and C at the position 341, two separate PCR reactions with either 
wild- or variant-specific forward primer and the common reverse primer were 
performed on GeneAmp PCR System 2700 (Applied Biosystems, Foster City, 
California). Both RFLP- and AS-PCR products were analyzed by gel electrophoresis 
on 1.2% agarose gel.  
 
Furthermore, coding regions of the NAT2 gene were amplified, purified and sequenced 
in both forward and reverse directions, using the ABI PRISM™ BigDye terminator 
cycle sequencing ready reaction kit version 3.1 (Applied Biosystems, Foster City, 
California) and ABI Prism 377 DNA sequencer. NAT2 sequence chromatograms were 
analyzed using software FinchTV version.1.4.0 (http://www.geospiza.com) and aligned 
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with the NAT2 reference sequence (http://www.ncbi.nlm.nih.gov; GenBank reference: 
NM 000015.2) for SNPs identification. 
 
In addition, Serbian subjects (paper III) were genotyped for three common NAT1 
polymorphisms coding for the NAT1 fast acetylators phenotype, namely 445G>A, 
640T>A and 1088T>A. Genotyping for 445G>A and 640T>A was performed by real-
time PCR and the Taqman genotyping assays using the ABI 7500 FAST (Applied 
Biosystems, Foster City, California) (122). Genotyping for 1088T>A was performed as 
described by Henning et al. (123), using two-step (nested) AS-PCR reaction: first 
amplification that used one pair of primers was followed by AS-PCR for allelic 
discrimination, i.e. two separate PCR reactions with different forward primers and the 
common reverse primer. AS-PCR products were analyzed by gel electrophoresis on 
1.2% agarose gel.  
 
Genotyping of XO was not performed, since this gene is not considered significantly 
polymorphic (91, 101). 
 
3.3.2  Phenotyping 
Phenotyping of CYP1A2, CYP2A6, NAT2 and XO was performed using caffeine 
(Koffein; ACO AB, Helsingborg, Sweden) as a probe drug and measuring 
concentration of parent compound and its metabolites in plasma or urine samples. 
 
To estimate in vivo CYP1A2 enzyme activity (papers I, II), molar concentrations of 
caffeine (1,3,7-trimethylxanthine or 137X) and its metabolites paraxanthine (1,7-
dimethylxanthine or 17X) were determined in plasma samples according to Ghotbi at 
al. (27), using reversed-phase HPLC with UV detection. In short, caffeine and 
paraxanthine were extracted from 100µ plasma samples with 300 ml acetonitrile, after 
addition of 25 µl of 50 µM internal standard (β-hydroxyethyl-theophiline). The organic 
phase was evaporated to dryness at the room temperature under nitrogen. After 
resolving the residue in 50 µl mobile phase, 15 µl was injected into the column. All 
samples, standards and quality controls were measured in one run and in duplicate. The 
flow rate was 1.0 ml/min and the compounds were monitored at 273.0 nm. The 
retention time was 5.5 - 7.6 min and 11.5 – 16.7 min for paraxanthine and caffeine, 
respectively. Calibration curves were linear, with the coefficients of correlation higher 
than 99%. At 16.3 μM for caffeine and 10.3 μM for paraxanthine, withinday and 
between-day coefficients of variations were less than 10 and 5% respectively. The 
HPLC equipment for the caffeine assay included 402 Dilutor-Dispenser (Gilson Inc., 
Middleton, WI), 231 XL Sample Injector (Gilson Inc., Middleton, WI), Dionex P580 
Pump P480 (Dionex, Sunnyvale, CA) and 1010 Model Lambda - UV/VIS-Detektor 
(Bischoff, Leonberg, Germany). For the separation of molecules we used C18 Luna 
column (100 × 4.6 mm ID, 3 µm), and the precolumn Security Guard Cartridges C18, 4 
x 3 mm, both purchased from Phenomenex Inc., Torrance, CA. Chromatographic data 
were registered and processed by ELDS Win Pro v 1.1 software (Chromatography Data 
System, Svartsjö, Sweden). In vivo CYP1A2 enzyme activity was estimated by the 
17X/137X ratio (124). 
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To estimate in vivo CYP2A6 enzyme activity (paper V), high-performance liquid 
chromatography (HPLC) was used to determine the molar concentrations of caffeine 
metabolites 17X (1,7-dimethylxanthine or paraxanthine) and 17U (1,7-dimethyluric 
acid) in collected urine samples, according to Carillo et al. (125). In brief, 17X and 17U 
were extracted simultaneously with 4 ml chloroform/isopropanol, after the addition of 6 
μg/50 μl internal standard (N-acetyl-p-aminophenol) and 120 mg ammonium sulfate. 
The organic phase was evaporated to dryness at 45°C under nitrogen, the residue 
reconstituted in 200 μl mobile phase, and 50 μl injected onto a Ultrasphere-IP (5 μm 
particle size, 250 × 4.6 mm ID) reversed-phase column (Beckman Instruments, Madrid, 
Spain), eluted isocratically with acetic acid/acetonitrile/tetrahydrofuran/water 
(1:40:2:957 v/v). The flow rate was 1.0 ml/minute and the detection wavelength was 
280 nm. Standard curves were with the coefficients of correlation higher than 99%. The 
limits of detection for the metabolites were within the range of 0.1 to 0.3 μmol. 
Withinday and intra-assay coefficient of variation (CV) was less than 10% at all 
concentration levels and for all metabolites, and the accuracy was between 96% and 
105%. System Gold Microbore HPLC with 32 Karat Software (Beckman Instruments, 
Madrid, Spain) was used to process the HPLC data. In vivo CYP2A6 enzyme activity 
was estimated by the 17U/17X ratio (81, 87). 
 
In vivo NAT2 and XO enzyme activities (papers III, IV) were assessed by the 
caffeine urinary test, according to Carrillo et al. (125). Molar concentrations of caffeine 
metabolites AFMU (5-acetylamino-6-formylamino-3-methyluracil), 1X (1-methyl 
xanthine) and 1U (1-methyluric acid) were determined by HPLC method, as described 
above. In vivo NAT2 and XO enzyme activities were estimated by the AFMU/(AFMU 
+1X+1U) and 1U/(1U+1X) ratios, respectively (84, 110, 126). 
 
3.4  STATISTICAL ANALYSES 
All statistical analyses were performed with Statistica, version 7.1 (StatSoft Inc, Tulsa, 
OK, USA). For all statistical procedures, P<0.05 was considered as significant. 
 
The 17X/137X, 1U/(1U+1X), AFMU/(AFMU+1X+1U) and 17U/17X ratios were log-
transformed before statistical analyses, and their normality of distribution was assessed 
by Kolmogorov-Smirnov or Shapiro-Wilk test (papers I-V). Student’s t-test, Mann-
Whitney test or one-way analysis of variance (ANOVA) followed by the post-hoc 
analyses were used to determine the influence of different factors on CYP1A2 enzyme 
activity (papers I, II). Haplotype analysis was carried out using the population genetic 
software program Arlequin, version 3.11 (http://cmpg.unibe.ch/software /arlequin3), 
and chi-square test was used to compare obtained with expected allele frequencies, i.e. 
to test the consistency with the Hardy-Weinberg equilibrium (papers II-V). Kruskall-
Wallis analysis, ANOVA followed by the post-hoc analyses or multiple linear 
regression were used to assess the effect of possible influencing factors on NAT2 and 
XO activity (papers III, IV). Effect on CYP2A6 enzyme activity was tested by 
multiple regression analysis (paper V). 
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3.5  ETHICAL CONSIDERATIONS 
All subjects participated voluntarily in the studies after signing written informed 
consent. The study was conducted in accordance with the Declaration of Helsinki and 
its subsequent revisions, and approved by the ethics committees at the Karolinska 
Institutet, Stockholm, Sweden, No.2009/219-32 (papers I-V), the Medical Faculty, 
University of Kragujevac, Serbia, No.01-1995, No.01-4502, No.01-6427/6 (papers I-




4.1  CYP1A2  
Having analyzed only non-OC users, significantly higher CYP1A2 enzyme activity in 
heavy coffee consumers compared to non-heavy coffee consumers was observed in 
Swedish (n=149, P<0.0001; 95% CI of the mean difference 0.06, 0.16) and Serbian 
(n=100, P=0.0002; 95% CI of the mean difference 0.08, 0.21) subjects. In both 
populations, the observed difference remained significant when additionally controlling 
for smoking, i.e. when analysis was performed among Swedish (n=114, P=0.02; 95% 
CI of the mean difference 0.01, 0.12) and Serbian (n=72, P=0.003; 95% CI of the mean 
difference 0.04, 0.18) non-smokers. In smokers, however, only Swedes displayed 
higher CYP1A2 activity if heavy coffee consumers (n=35, P<0.0001; 95% CI of the 
mean difference 0.13, 0.33), while no significant difference was observed among 
Serbian smokers (n=28, P=0.77) (paper I).  
 
Effect of CYP1A2 genotype on enzyme activity was analyzed among non-OC users and 
non-smokers, and −163C>A polymorphism was detected as the only predictor. 
Significantly higher CYP1A2 activity was observed in carriers compared to non-
carriers of −163C>A polymorphism in both Swedish (n=42, P=0.016) and Serbian 
(n=17, P=0.022) heavy coffee consumers. The highest enzyme activity among heavy 
coffee consumers was detected in the −163A/A genotype group in both populations, 
observed as significantly higher compared to homozygous carriers of variant type allele 
among Swedes (P=0.036; 95% CI of the mean difference 0.01, 0.23) and Serbs 
(P=0.001; 95% CI of the mean difference 0.09, 0.36). However, among non-heavy 
coffee consumers no significant effect of −163C>A polymorphism on CYP1A2 
enzyme activity was observed in either Swedes (n=72, P≥0.31) or Serbs (n=47, 
P≥0.15). In addition, the inducing effect of heavy coffee consumption on CYP1A2 
activity was observed only in carriers of −163A/A genotype in both Swedes (n=46, 
P<0.0001; 95% CI  of the mean difference 0.08, 0.22) and Serbs (n=22, P=0.005; 95% 
CI of the mean difference 0.06, 0.28) (paper II). 
 
When controlling for the effect of cigarette smoking, heavy coffee consumption and 
OC use, significantly higher CYP1A2 enzyme activity (P=0.0003; 95% CI of the mean 
difference -0.14, -0.04) was observed in Swedes (n=72) compared to Serbs (n=54) 
(paper I).  
 
4.2  CYP2A6  
Except for the 1436G>T polymorphism that was absent in both populations, the 
distribution of CYP2A6 variant alleles and genotypes was significantly different 
between Swedes and Koreans (P≤0.002). The distribution of genotype groups, 
appointed according to the presence of functional (*1A, *1x2, or *1B1) or less 
functional/non-functional CYP2A6 alleles (*4, *7, *8, *9 and *10), also significantly 
differed between the populations (P<0.0001), revealing rapid (95% CI of the difference 
in proportions 0.44, 0.62) and slow (95% CI of the difference in proportions -0.32, -
0.18) genotype groups as the most prevalent among Swedes and Koreans, respectively. 
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CYP2A6 genotype significantly affected enzyme activity in both populations (P=0.004), 
while no effect of sex (P=0.14), age (P=0.32), cigarette smoking (P=0.39) or OC use 
(P=0.59) was observed (paper V). 
 
The 17U/17X ratios in Swedes (n=190) ranged from 0.00 to 2.81 (median: 0.50), while 
in Koreans (n=144) were between 0.00 and 1.96, with the median value of 0.22. The 
probit transformation indicated common antimode at 0.01, with 3.16% of Swedes and 
18.75% of Koreans having phenotype of slow metabolizer (P<0.0001; 95% CI of the 
difference in proportions -0.22, -0.09). CYP2A6 enzyme activity was significantly 
higher in Swedes compared to Koreans (P=0.0001; 95% CI of the median difference 
0.23, 0.46). The observed differences between the two populations remained significant 
when controlling for the genotype effect, i.e. within rapid (P=0.0007; 95% CI of the 
median difference 0.08, 0.40) and intermediate (P=0.04) genotype groups (paper V). 
 
4.3  NAT2 
The AFMU/(AFMU+1X+1U) ratios in Serbs ranged from 0.05 to 0.64 (median: 0.33), 
with clear antimodes at 0.09 and 0.25 that appointed 9% (n=9), 36% (n=36) and 55% 
(n=55) of Serbian subjects for slow, intermediate and rapid acetylators, respectively 
(paper III). The AFMU/(AFMU+1X+1U) ratios in Swedes and in Koreans were 
within the range from 0.00 to 0.53 (median: 0.02) and from 0.00 to 0.44 (median: 0.06), 
respectively. The antimode at 0.16 observed in Koreans denoted 25.9% of Korean 
subjects as rapid metabolizers, while in only 6.2% of Swedes the 
AFMU/(AFMU+1X+1U) ratios were above the same value (P<0.0001; 95% CI of the 
difference in proportions -0.28, -0.11) (paper IV).  
 
Comparison between Swedes and Koreans revealed latter to have significantly higher 
NAT2 activity, and the difference remained significant when controlling for the 
influence of cigarette smoking, sex, or OC use (P<0.0001), as well as NAT2 genotype 
(P=0.016). Stratified by genotype, Koreans display higher enzyme activity compared to 
Swedes among carriers of at least one wild type NAT2*4 allele (P=0.004), while similar 
tendency of higher enzyme activity in Koreans than in Swedes was observed among 
slow acetylators (P=0.31) (paper IV).  
 
With the frequency of 43%, the most common NAT2 haplotype in Serbs was NAT2*5, 
followed by NAT2*6 that was present in 28% of Serbian subjects (paper III). Similar 
distribution was observed in Swedes, with 47% and 28% of subjects having NAT2*5 
and NAT2*6 haplotype, respectively (paper IV). On the other hand, 65% of Koreans 
were carriers of wild type NAT2*4, NAT2*6 had a frequency of 23%, while NAT2*5 
was extremely rare (0.2%) (paper IV).  
 
When stratified based on the presence or absence of functional NAT2*4, NAT2*12 or 
NAT2*13 allele, Swedes and Koreans significantly differed in terms of distribution of 
genotype groups (P<0.0001). In Swedes, carriers of two, one and no functional alleles 
occurred with the frequencies of 8.85%, 29.20%, and 61.95%, respectively, whereas in 
Koreans the respective percentages were 40.67%, 48.67%, and 10.67% (paper IV). In 
Serbs, however, both alleles were functional in 4.9% of subjects, genotypes containing 
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only one functional allele had a frequency of 45.5%, while no functional alleles had 
49.6% of the population (paper III). 
 
Significant NAT2 genotype-phenotype association was detected in all three 
populations: in Serbs (P<0.0001) (paper III), Swedes (P=0.03) and Koreans (P=0.008) 
(paper IV). Due to unexpectedly high frequency of rapid acetylators observed in Serbs, 
genotype-phenotype correlation was investigated in each of the Serbian subjects 
separately. It was observed that, of all slow/intermediate acetylators (AFMU/(AFMU+ 
1X+1U) ratio bellow 0.25) who had their genotype determined (n=44), in 93.2% 
observed phenotype was in agreement with the genotype, i.e. subjects were 
homozygous for the defective variant alleles. However, only 84.9% concordance with 
the genotype was observed within the rapid acetylator group (AFMU/(AFMU+1X+1U) 
ratio above 0.25, n=53), that is, there were 8 subjects carrying both defective alleles, yet 
displaying high enzyme activity. Described NAT2 genotype-phenotype discordance 
could not be explained by NAT1 gene polymorphism, as there was no significant 
differences in NAT1 alleles and genotypes frequency distribution between NAT2 
phenotype (P=0.36) or genotype groups (P=0.07) (paper III).   
 
No significant influence of smoking on NAT2 activity was observed in either Serbs 
(P=0.57) (paper III), Swedes (P=0.14) or Koreans (P=0.05) (paper IV). Similarly, 
there was no significant difference between men and women within Serbian (P=0.94) 
(paper III), Swedish (P=0.74) and Korean (P=0.39) population (paper IV). On the 
other hand, significant correlation of OC use and NAT2 activity was observed in 
Swedish women (P=0.007; 95% CI of the median difference -0.53, -0.21), users (n=33, 
median: 0.04) having significantly higher enzyme activity compared to non-users 
(n=38, median: 0.02) (paper IV). This effect could not be evaluated in other two 
populations, as none and only one woman used oral contraceptives in Serbs and 
Koreans, respectively (paper III, IV).  
 
4.4  XO 
The 1U/(1U+1X) ratios in Swedes and Koreans ranged from 0.01 to 0.98 in former and 
from 0.00 to 0.98 in latter, with the median values of 0.46 and 0.48, respectively. The 
common antimode at 0.08 identified 6.4% of Swedes and 9.5% of Koreans as slow 
metabolizers. In terms of XO activity, no significant difference between the two 
populations was detected (P=0.40) (paper IV). 
 
XO activity was significantly influenced by sex in Swedes (P=0.003; 95% CI of the 
median difference 0.06, 0.32), but not in Koreans (P=0.43). In Swedes, higher 
1U/(1U+1X) ratio was observed in women (n=70, median: 0.53) compared to men 
(n=39, median: 0.34), and the effect remained significant after the OC users were 
excluded from the comparison (P=0.01). OC use (P=0.09) and cigarette smoking 
(P=0.15) did not affect XO activity in either of the populations (paper IV). 
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5 DISCUSSION 
5.1  CYP1A2 
In the present study, the main findings related to CYP1A2 activity are enzyme 
induction by habitual heavy coffee consumption in carriers of −163C>A CYP1A2 
polymorphism, and higher CYP1A2 enzyme activity in Swedish compared to Serbian 
population (paper I, II).  
 
Effect of heavy coffee consumption has been investigated in Serbian and Swedish 
healthy volunteers, none of which was using any medications, including oral 
contraceptives. Possible competitive inhibition was avoided by abstaining from intake 
of any caffeine-containing food, beverage and medication for at least 24 h before and 
during the study (114, 124). The results demonstrated that daily consumption of at least 
three cups of coffee increased CYP1A2 enzyme activity in all Swedes and Serbs. Since 
it is known that cigarette smoking induces CYP1A2 enzyme activity (52), effect of 
heavy coffee consumption among Swedes and Serbs was additionally analyzed when 
controlling for this confounding factor. Among non-smokers in both populations, heavy 
coffee consumers displayed higher enzyme activity compared to non-heavy coffee 
consumers. Similar results were obtained among Swedish smokers, but we were not 
able to show the same effect in Serbian smokers due to the low number of subjects in 
this group (paper I).  
 
The general mechanism of CYP1A2 induction is well known and includes ligand-
dependent activation of aryl hydrocarbon receptor (AHR) - aryl hydrocarbon receptor 
nuclear translocator (ARNT) pathway (48, 127). Upon ligand binding, AHR 
translocates from cytoplasm into the nucleus, and with ARNT protein, already present 
in the nucleus, forms a heterodimer. This complex then recognize and binds to one of 
the several xenobiotic response elements (XRE), localized within the promoter region 
of CYP1A2 gene, and in turn induce transcription activation (52, 128, 129). The ligands 
that activate AHR could be certain environmental chemicals, of which the most 
common are polycyclic aromatic hydrocarbons (PAHs) (127). PAHs are produced by 
incomplete combustion processes of organic material at high temperatures (130, 131), 
and could be found in cigarette smoke and grilled meat – both known inducers of 
CYP1A2 activity (48, 52, 132).  
 
Coffee is a complex chemical mixture of over 1000 different chemicals, with caffeine, 
its best-known component, participating with only 1 % (34). According to previous 
investigations, caffeine has a very low affinity for the AHR (133). Furthermore, 
CYP1A2 induction was observed to be more dependent on a regular coffee 
consumption than on an overall caffeine intake (63), suggesting that effect of some 
other coffee constituent might be more important than the effect of caffeine itself. In 
addition, in vitro studies reported that coffee consumption up-regulate glucuronidation 
by AHR signaling, but that this process takes place independently of caffeine (134). At 
the same time, all types of coffee beans have to be roasted before preparation and the 
temperature during roasting reaches up to 260°C (34, 135). Thus, the concentration of 
PAHs, which are already present in green coffee beans, increases during the roasting 
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process (135), and reach up to 1.8 μg of PAHs per liter of coffee brew samples (136). 
According to our results, regular heavy coffee consumption induces CYP1A2 activity. 
Based on the data from the literature, we presume polycyclic aromatic hydrocarbons to 
be at least partly responsible for this effect. 
 
CYP1A2 is known to be polymorphic, with several polymorphisms having an impact on 
drug metabolism (48, 52). Of those, substitution C>A at position −163 is one of the 
most common in Caucasians, with frequencies that range from 33.8% in British (137) 
to 71.4% in Swedish population (27). Its importance for CYP1A2 enzyme activity was 
first observed by Sachse et al. (54) as higher enzyme inducibility by cigarette smoking 
in the presence of −163A/A genotype. Several subsequent studies (27, 56, 138, 139), 
but not all (57, 140, 141), confirmed this observation by reporting higher CYP1A2 
enzyme activity in the presence of CYP1A2 inducers, such as cigarette smoking or 
omeprazol.  
 
To investigate the possible effect of CYP1A2 genetic polymorphism on enzyme 
induction by heavy coffee consumption, we compared enzyme activity among Serbian 
and Swedish heavy and non-heavy coffee consumers, controlling for the influence of 
cigarette smoking and OC use. In heavy coffee consumers, the highest CYP1A2 
enzyme activity was detected in carriers of -163A/A genotype. The inducing effect of 
heavy coffee consumption was observed only in subjects homozygous for the variant -
163A allele. In non-heavy coffee consumers, influence of -163C>A was not observed 
(paper II).  
 
To the best of our knowledge, this is the first study to report increased CYP1A2 
inducibility by heavy coffee consumption in carriers of −163A/A genotype. Significant 
genotype-phenotype association was analyzed and confirmed independently in two 
different populations, regardless of possible linkage disequilibrium with other CYP1A2 
polymorphisms. It is interesting to note that among all heavy coffee consumers 
inducing effect was observed only in carriers of −163A/A genotype, while among all 
carriers of −163A/A genotype higher enzyme activity was observed only in heavy 
coffee consumers. Based on these observations, both −163A/A genotype and an 
inducer, such as heavy coffee consumption, seem to be necessary for the CYP1A2 
induction. Our results suggest that regular heavy coffee consumption might be a 
possible confounding factor for the discrepant findings in studies investigating the 
association of −163C>A CYP1A2 polymorphism with CYP1A2 enzyme induction. 
 
Previous studies, comparing black with white populations (62, 65), or Koreans with 
Swedes (27), reported the influence of ethnicity on CYP1A2 activity. Within Caucasian 
population, significantly higher CYP1A2 activity has been observed among residents of 
Germany compared to subjects living in Bulgaria and Slovakia (63). In the present 
study, two populations, both of Caucasian origin but representing different ethnic 
groups, were compared in terms of CYP1A2 enzyme activity. The comparison revealed 
significantly higher enzyme activity in Swedes compared to Serbs (paper I). 
 
The effects of ethnicity on drug metabolism can be determined by both genetic and 
environmental factors, including diet, lifestyle and concomitant use of medications (9). 
In the present study, inter-ethnic variation in CYP1A2 enzyme activity was investigated 
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by comparing healthy unrelated Swedish and Serbian volunteers, who were not using 
any medications, including OC. The frequency of −163C>A CYP1A2 polymorphism 
was similar between the population, and the influence of cigarette smoking and heavy 
coffee consumption was ruled out by excluding smokers and heavy coffee consumers 
from the comparison. The reason for the observed difference remains to be additionally 
investigated, with other CYP1A2 genetic variants, epigenetic regulation or unreported 
intake of herbal preparations as possible explanations (25, 52, 127, 142, 143).  
 
5.2  CYP2A6  
Regarding CYP2A6, the most important observation of this study is the difference 
between Swedish and Korean population in terms of both CYP2A6 genotype and 
enzyme activity. Unlike sex, age, cigarette smoking and OC use, CYP2A6 genotype 
significantly affected CYP2A6 enzyme activity (paper V).  
 
Based on the earlier investigations, CYP2A6 genetic variation has been suggested to be 
the leading cause for the variability in enzyme activity (69, 74, 75, 86). In the present 
study, Swedish and Korean subjects were genotyped for functional variant alleles 
previously found in Caucasians and/or Asians, and the results corresponded well with 
the earlier reports (75-77, 144-149). In Swedes, the most frequently found were rapid 
genotypes, consisting of both functional alleles, whereas in Koreans the most numerous 
were the carriers of slow genotype with both alleles nonfunctional. As expected (73, 
150), the effect of genotype on CYP2A6 activity was confirmed in both populations 
(paper V).  
 
Inter-ethnic differences in CYP2A6 activity have already been studied, and 
significantly lower enzyme activity was observed in African Americans and Asians 
compared to Caucasians in general (151, 152). Additionally, when comparing with 
black and white populations and between each other, Japanese displayed the lowest and 
Koreans the highest CYP2A6 activity (146, 148). In the present study we detected 
higher CYP2A6 activity in Swedes compared to Koreans (paper V). Since rapid 
CYP2A6 genotypes were more frequent in Swedes and slow in Koreans, the observed 
difference in enzyme activity between the populations could be explained by genotype 
effect. Nevertheless, after stratification according to the genotype Swedes still 
displayed higher enzyme activity, indicating that, although it contributes to, the 
investigated CYP2A6 genetic polymorphisms cannot fully explain inter-ethnic 
variability in CYP2A6 enzyme activity. Possible reasons for the observed difference 
could include other CYP2A6 genetic variants, epigenetics or diet (146, 148, 153).  
 
Considerable controversy about possible effect of sex on CYP2A6 activity dwells in 
the available literature. Some of the previous studies, investigating Caucasians (75, 82, 
152, 154), Africans (83, 148), and Asians (155), reported higher enzyme activity in 
women compare to men. Since increased enzyme activity have been observed in OC 
users too (72, 82), female sex hormones were suggested as responsible for the inducing 
effect of on CYP2A6 activity (82). However, other studies failed to find any significant 
sex differences in enzyme activity in either Caucasians (81, 84, 148, 156) or Asians 
(157). Similarly, in the present study we did not observe any effect of either sex or OC 
use on CYP2A6 activity in Swedes or in Koreans (paper V). It is known that sex-
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related differences in pharmacokinetics could be important determinants of inter-
individual variation in drug response (3, 4, 8-10), with body mass index and hormonal 
status as the most likely underlying cause (158). Yet, many of the studies on sex-based 
inter-individual differences in drug metabolizing enzyme activity have been performed 
in small number of subjects, thus producing inconclusive results (158). Regarding 
CYP2A6, the influence of sex and OC use on enzyme activity remains controversial, 
thus future studies, taking account both sample size and possible confounders, such as 
body weight or hormonal replacement therapy, will be needed to resolve this issue. 
 
Although the hypothesis that activity of CYP2A6 activity could change with age was 
not widely investigated, some of the studies did describe significantly higher enzyme 
activity in older individuals (72, 154, 156). Consistently with the opposite reports, in 
the present study, involving subjects from 18 to 60 years old, no association of 
CYP2A6 activity with age neither in Swedes nor in Koreans was observed (paper V). 
Our finding is in accordance with the experimental data demonstrating that the content 
and activities of various CYP450 enzymes practically do not decline with age in 
healthy subjects (159-162). Most probably, seeming age effect on CYP2A6 activity 
observed in several previous studies might be the due to unrecognized chronic liver 
disease or unreported intake of CYP2A6 inducers or inhibitors (159-161). 
 
The effect of cigarette smoking on CYP2A6 activity, assuming competitive enzyme 
inhibition by nicotine, was much more intensively studied (70, 81). Some of the studies 
identified expected decrease in enzyme activity in smokers (75, 81, 83, 145), while 
others did not observe any influence of cigarette smoking habit on CYP2A6 (72, 84, 
156). The results of the present study are consistent with the latter reports, as sought 
effect of smoking was not detected in either Swedes or Koreans (paper V). It is well 
known that nicotine is almost exclusively metabolized by the CYP2A6 enzyme (86), 
thus the competitive inhibition of caffeine metabolism by cigarette smoking could be 
expected. Yet, since the conversion of 17X to 17U, which depends on CYP2A6, is not 
saturable in physiological conditions (163, 164), the nicotine effect, if exists, might not 
be very significant, necessitating larger sample size for detection. In addition, 
unreported intake of herbal preparations or nicotine replacement therapy should be 
considered as confounders. 
 
5.3  NAT2 
The most important findings of this study related to NAT2 include higher enzyme 
activity in Koreans compared to Swedes (paper IV), and unprecedentedly high 
prevalence of rapid acetylators in Serbian population (paper III). All three populations 
differed in terms of NAT2 genotype distribution, but in all significant genotype-
phenotype association was detected (paper III, IV). Yet, in Serbs partial discordance 
between rapid acetylator phenotype and NAT2 genetic background was observed, 
which could not be explained by NAT1 gene polymorphism either (paper III). Sex and 
cigarette smoking did not affect NAT2 activity in either of the populations (paper III, 
IV), while in Swedish women OC users had higher enzyme activity (paper IV).  
 
NAT2 gene is known to be highly polymorphic (92, 95). In the present study, the most 
important nonsynonimous gene polymorphisms have been determined, and subjects 
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were stratified according to the genotype to either fast (carriers of at least one NAT2 
functional allele) or slow genotype group (165, 166). Additionally, fast genotype group 
was further divided into intermediate and rapid group, consisting of carriers of one and 
two functional alleles, respectively. The allele frequencies observed in Serbs, Swedes 
and Koreans were as expected for populations belonging to Caucasians and Asians, 
respectively. (166-170). Comparison among the populations revealed significant 
difference in the distribution of the NAT2 genotypes. Namely, slow genotype was the 
most prevalent in Swedes and fast genotype in Koreans, while in Serbs both slow and 
fast genotypes were equally distributed (paper III, IV). 
 
Significant correlation of NAT2 genotype with N-acetylation capacity has already been 
reported by a number of studies, designating genetics as the most important 
determinant of inter-individual variation in NAT2 activity (89, 95, 98, 167). As 
expected, our study confirmed significantly high NAT2 genotype-phenotype 
correlation in all three investigated populations (paper III, IV). Nevertheless, certain 
discordance was observed in Serbian population, as the genotype did not correspond to 
observed acetylation status in all subjects. Namely, there were subjects having both 
functional alleles and displaying intermediate phenotype, as well as subjects carrying 
both defective alleles, yet displaying rapid phenotype (paper III). Although unusual, 
similar NAT2 genotype-phenotype discordance has already been reported in up to 10% 
of the population (89, 95, 96, 167). Other variations of NAT2 gene were suggested as a 
plausible explanation for intermediate acetylators with rapid genotype finding (167), 
but sequencing of the NAT2 coding region did not reveal any additional 
nonsynonymous polymorphism. Thus, either unknown variation within promoter 
region (97) or factors other than genetic variations, such as epigenetic influences (98) 
diet (79), or unreported traditional medications (171), might be responsible for the 
observed deviation within intermediate acetylator group. On the other hand, the 
presence of less functional allele renders NAT2 genotype slow regardless of other 
polymorphisms, thus additional NAT2 genotyping could not explain discordance 
observed in rapid acetylator group. However, as NAT1 participates in caffeine 
metabolism by contributing to AFMU formation (166), NAT1 genotyping was 
considered to be of importance: over-representation of NAT1 fast alleles might have 
increased formation of AFMU and consequently AFMU/(AFMU+1X+1U) ratio, thus 
causing misclassification of NAT2 acetylators phenotype as rapid. To test the 
hypothesis, subjects were additionally genotyped for SNPs in the NAT1 gene 
responsible for the fast NAT1 acetylation activity (95, 172-174). Nevertheless, fast 
NAT1 alleles were similarly distributed among both NAT2 genotype-phenotype 
concordant and discordant subjects, and did not affect AFMU/(AFMU+1X+1U) ratio. 
Therefore, NAT1 genetic polymorphism was excluded as an underlying cause for the 
observed NAT2 genotype-phenotype discordance within rapid acetylator group, and 
unreported environmental factors were suggested instead. 
 
N-acetylation activity within populations usually follows bimodal or trimodal pattern, 
discriminating slow and intermediate from the rapid acetylator phenotype (62, 84, 166, 
167, 175). In our study, Swedes displayed unimodal and Koreans bimodal NAT2 
activity distribution, with lower N-acetylation capacity in Swedes compared with 
Koreans (paper IV). The observed difference was in accordance with the population-
specific NAT2 genotype distribution patterns, as the frequency of defective variant 
 24 
alleles coding for the slow acetylator phenotype was higher in Swedes compared with 
Koreans. Inter-ethnic variations in NAT2 enzyme activity have already been observed 
(62, 79, 89, 90), including report of higher N-acetylation capacity in Caucasians 
compared to Asians (176), but the genotype effect was rarely considered. When we 
compared NAT2 activity between Swedes and Koreans while controlling for the NAT2 
polymorphism, the difference remained significant among carriers of fast genotype, 
while a similar tendency was observed between slow genotype groups (paper IV).  
 
On the other hand, Serbs display trimodal distribution of NAT2 enzyme activity, with 
lower and upper antimode values at 0.09 and 0.25, respectively (paper III). Previous 
studies, using the same metabolic ratio as an index of NAT2 activity, set the lower limit 
for the rapid acetylators’ phenotype between 0.2 and 0.3, regardless of the distribution 
pattern (62, 175, 177). This common cut-off point allowed us to compare our results 
with the previous reports for Caucasians, where the frequency of rapid acetylators, 
exceeding the similar cut-off point, was 44.9% or less (62, 84, 166), and slow 
acetylators phenotype was predominant. In contrast, our study revealed slow acetylator 
as the least common phenotype in Serbs, while 55% of subjects were designated as 
rapid acetylators, having AFMU/(AFMU+1X+1U) urinary ratio above upper antimode 
value of 0.25 (paper III).  This unprecedented high prevalence of rapid acetylators in a 
white population could not be explained by either NAT2 or NAT1 genotypes, as both 
were found at frequencies consistent with the previous reports (122, 166-168, 178, 
179). Our results of both comparison between Swedes and Koreans and phenotyping of 
Serbian population indicate that, in addition to NAT2 genotype, ethnicity should be 
considered an important factor in treating patients with NAT2 metabolized drugs (169, 
180). Inter-ethnic difference in N-acetylation capacity might be due to epigenetics, diet, 
or traditional medications (79, 98, 169, 175). 
 
In agreement with the earlier reports (62, 79, 98, 181), sex or cigarette smoking did not 
affect NAT2 acetylation capacity in Serbs, Swedes or Koreans (paper III, IV). On the 
other hand, association between OC use and higher NAT2 activity was observed in 
Swedish women. Since only one Korean and none of the Serbian women used oral 
contraceptives, the finding could not be confirmed. It is known from previous animal 
studies that certain hormones can induce NAT2 via hormone-responsive elements (89). 
Yet, previous human study on OC use and NAT2 activity failed to find any significant 
association (181). Thus, to investigate the effect of steroid hormones on acetylation 
capacity in humans, as well as to explain the underlying mechanism of induction, 
additional studies will be necessary.  
 
5.4  XO 
The main findings of the present study related to XO comprise the lack of inter-ethnic 
difference between Swedes and Koreans and higher enzyme activity in Swedish 
women compared to men. Cigarette smoking and OC use did not affect XO activity in 
either of the populations (paper IV). 
 
As a multifunctional enzyme involved in metabolism of both endogenous and 
exogenous substrates (104), XO has been widely investigated (62, 84, 108-110, 175, 
181). Yet, although lower XO activity has been observed in black compared to 
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Caucasians (62), inter-ethnic differences were mainly reflected in the enzyme activity 
distribution pattern. Namely, in Caucasian populations XO activity were usually 
unimodally distributed (81, 84, 181), while others displayed bimodal distribution, with 
poor metabolizers ranging from 4% in Spaniards and Ethiopians (109, 110) up to 11% 
in Japanese (175). In the present study, in accordance with earlier studies comparing 
Caucasians and Chinese (64), comparison between Swedes and Koreans revealed the 
lack of interethnic variability in XO activity. Nevertheless, both Swedes and Koreans 
displayed bimodal distribution of XO activity (paper IV). In Koreans as an Asian 
population poor metabolizer phenotype was expected to be present (175), and its 
frequency corresponded well with the previously reported data. On the other hand, 
additional investigations, taking into account both XO genetic polymorphism (101) and 
environmental factors, will be needed to explain the slow metabolizer phenotype in the 
Swedish population. 
 
Most of the previous studies did not observe any correlation between sex and XO 
enzyme activity (64, 108, 110, 175, 181). Nevertheless, Relling et al. (62) and 
Guerciolini et al. (102) reported higher and lower enzyme activity in women, 
respectively. In addition, Brown et al (182) described a positive association between 
female hormone levels and OC use with XO activity in human breast milk. In the 
present study, women displayed higher XO activity in Swedes but not in Koreans, 
while the influence of OC use was not observed (paper IV). Our results suggest sex as 
a factor to be considered for dose adjustments in Swedish patients treated with drugs 
metabolized by XO. On the other hand, it is generally accepted that cigarette smoking 
does not affect XO activity (108, 110, 175, 181). As expected, cigarette smoking did 
not affect XO activity in either Swedes or Koreans (paper IV). 
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6 CONCLUSIONS 
• Habitual heavy coffee consumption induces CYP1A2 enzyme activity in 
carriers of CYP1A2 −163A/A genotype. 
• Swedes display significantly higher CYP1A2 activity compared to Serbs, and 
the observed difference is not due to CYP1A2 genetic polymorphism, cigarette 
smoking, oral contraceptive use or heavy coffee consumption. 
 
• CYP2A6 genotype, but not sex, age, cigarette smoking and OC use, 
significantly affect CYP2A6 enzyme activity.  
• Swedes display significantly higher CYP2A6 activity compared to Koreans, 
and the observed difference is mainly, but not entirely due to lower frequency 
of defective variant alleles in former compared to latter. 
 
• NAT2 genotype, but not sex and cigarette smoking, significantly affect NAT2 
enzyme activity. In Swedish women, oral contraceptive use is associated with 
higher NAT2 enzyme activity. 
• Koreans display significantly higher NAT2 enzyme activity compared to 
Swedes and the observed difference is mainly, but not entirely due to lower 
frequency of defective variants alleles in former compared to latter. 
• Serbs differ from other Caucasians in terms of N-acetylation capacity, due to 
unprecedented high prevalence of rapid acetylator phenotype in the population. 
Partial NAT2 genotype-phenotype discordance observed in Serbian rapid 
acetylators could not be explained by NAT1 gene polymorphism. 
 
• Cigarette smoking and OC use do not affect XO enzyme activity. In Swedes, 
female sex is associated with higher XO enzyme activity. 
• There is no inter-ethnic difference between Swedes and Koreans in terms of XO 
enzyme activity.  
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